Pharming receives FDA approval for Joenjaas to treat rare immunodeficiency
Joenja is indicated for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), which is caused by gain of function…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Mar 23
Joenja is indicated for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), which is caused by gain of function…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Mar 23
Designated as GS-6791, NX‑0479 is a bivalent degrader which is the first development candidate resulting from the previously…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Mar 23
The company will use the funding to advance its portfolio which comprises three novel antibody treatments that are…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Mar 23
The deal will add Provention Bio’s Tzield disease-modifying treatment for delay of Stage 3 type 1 diabetes to…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Mar 23
The late-stage trial compared the lung cancer drug with placebo in the late-stage trial in 682 patients having…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Feb 23
Hemgenix is an adeno-associated virus (AAV)-based gene therapy indicated for the treatment of severe and moderately severe haemophilia…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Feb 23
Bavarian Nordic will obtain rights to Emergent’s vaccine candidates, Vivotif to prevent typhoid fever, Vaxchora to prevent cholera,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Jan 23
The firm is developing the OR-449 for both the adult and paediatric forms of ACC as well as…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Jan 23
The acquisition builds on a multi-year strategic collaboration between BioNTech and InstaDeep and is expected to add around…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Jan 23
Anima Biotech will get a $42m upfront payment with the possibility of further payments towards research and development…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates